Neoadjuvant Fluzoparib in Germline BRCA-mutated Three-negative Breast Cancer Breast Cancer
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: TNBC - Triple-Negative Breast Cancer
Interventions: DRUG: Fluzoparib+Paclitaxel|DRUG: Epirubicin+Cyclophosphamide
Sponsor: The First Affiliated Hospital with Nanjing Medical University
Collaborators: Jiangsu HengRui Medicine Co., Ltd.